(713.8) Protective Effect of Hydrogen Sulphide in Cardioplegia on Global Myocardium Ischemia-reperfusion Injury

Poster Board Number: E52

Ji-Yang Zuo (The Institute of Cardiovascular Diseases amp; Department of Cardiovascular Surgery, TEDA International Cardiovascular Hospital, Tianjin University amp; Chinese Academy of Medical Sciences), Hai-Tao Hou (The Institute of Cardiovascular Diseases amp; Department of Cardiovascular Surgery, TEDA International Cardiovascular Hospital, Tianjin University amp; Chinese Academy of Medical Sciences), Zhi-Gang Liu (The Institute of Cardiovascular Diseases amp; Department of Cardiovascular Surgery, TEDA International Cardiovascular Hospital, Tianjin University amp; Chinese Academy of Medical Sciences), Qin Yang (The Institute of Cardiovascular Diseases amp; Department of Cardiovascular Surgery, TEDA International Cardiovascular Hospital, Tianjin University amp; Chinese Academy of Medical Sciences), Guo-Wei He* (The Institute of Cardiovascular Diseases amp; Department of Cardiovascular Surgery, TEDA International Cardiovascular Hospital, Tianjin University amp; Chinese Academy of Medical Sciences, Drug Research and Development Center, Wannan Medical College, Department of Surgery, Oregon Health and Science University)

Objective: The endogenous gaseous transmitter hydrogen sulfide (H2S) is an important regulator of the cardiovascular system and is reported to have cardioprotective activity against ischemia/reperfusion (I/R) injury. We investigated the cardioprotective effect of H2S added in cardioplegia against I/R injury in global cardioplegic arrest.

Methods:  Isolated Wistar rat hearts were perfused in Langendorff apparatus and underwent 30 min perfusion, 120 min cold ischemia, and 90 min reperfusion. The rats were randomly divided into 5 groups: Control group, ischemic and reperfusion (I/R), St. Thomas cardioplegia (St. Thomas +I/R), St. Thomas plus H2S donor NaHS (NaHS+St.Thomas+I/R), St.Thomas plus NaHS and glibenclamide (an antagonist of KATP channel; NaHS+Glib+St.Thomas+I/R). The following indices were compared among the groups: the change of left ventricular systolic pressure (LVSP), left ventricular end diastolic pressure (LVEDP), heart rate, heart rhythm, and coronary blood flow.  The difference in left ventricular developed pressure (LVDP), the maximum left ventricular pressure rise rate (+dp/dtmax), and the maximum left ventricular pressure drop rate (-dp/dtmax) were also compared. Western blot was used to detect the changes of related myocardial enzymes among different groups.

Results: NaHS+St.Thomas+I/R treatment significantly improved cardiac function (LVSP, LVDP, +dp/dtmax and -dp/dtmax) compared to other groups (plt;0.05), although no significant differences  on coronary flow and heart rate were observed. After reperfusion, the frequency of ventricular arrhythmia in I/R group and St.Thomas+I/R group was significantly higher than that in NaHS+St.Thomas+I/R group. Further, the expression of cardiac Troponin T, troponin I, and creatine kinase in the NaHS+St.Thomas+I/R group was significantly lower than that in other groups (plt;0.05). 

Conclusion: Cardioplegia containing H2S confers significant protection against global I/R injury during cold cardioplegic arrest. This effect is associated with opening of the myocardial KATP channels. Therefore, H2S may be a useful adjunct to cardioplegic solutions in heart surgery.

lt;igt;Supported by the National Natural Science Foundation of China [82170353 amp;amp; 81870288 amp;amp; 81870227]; the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2020-PT310-007 amp;amp; 2019XK310001]; Tianjin Binhai New Area Health Commission [2019BWKY011]; Tianjin Science and Technology Project [18PTZWHZ00060]; TEDA International Cardiovascular Hospital[2019-TD-003].lt;/igt;